Adrenaline: A Lifeline for Rapid Drug Desensitization in Hypersensitive Patients
Journal of Investigational Allergy and Clinical Immunology · 2025
DOI: 10.18176/jiaci.1075 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Investigational Allergy and Clinical Immunology, 2025. Verfasst von Johana Gil-Serrano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Department, University Hospital Vall d'Hebron, Barcelona, Spain. Hauptthemen laut MEDLINE: Drug Hypersensitivity, Desensitization, Immunologic, Epinephrine, Antineoplastic Agents.
Abstract (Originalsprache)
Background
Chemotherapeutic agents (CMTs) and monoclonal antibodies (mAbs) are common causes of drug allergy, which is often managed using rapid drug desensitization (RDD). Despite its effectiveness, RDD can be hampered by severe breakthrough reactions (BTRs), potentially leading to failure of the procedure.
Objective
To evaluate the usefulness and safety of adrenaline infusion (AI) as an adjuvant during RDD in patients who experience severe drug hypersensitivity reaction (DHR) during standard desensitization protocols.
Methods
Retrospective observational study, analyzing data from patients who underwent RDD to CMTs or mAbs in a tertiary hospital from January 2015 to June 2024. We included patients who required AI to safely achieve RDD after a severe initial DHR or failure of a standard RDD protocol due to repeated DHRs. Comorbidities, adrenaline doses, and adverse events (AEs) were assessed.
Results
RDD with AI was administered in 42 patients. Of these, 77% (n=32) were women, and the mean age was 57 years. The most frequently involved drugs were platinum salts (58%), mAbs (26%), and taxanes (14%). A total of 151 RDDs were performed with AI. Skin tests were positive in 69% of patients. The most frequent initial BTR (65%) was moderate or severe anaphylaxis. The most common AEs induced by AI were tremor (14%) and tachycardia (7%), which resolved after reducing the AI infusion rate. The median (IQR) cumulative dose of adrenaline administered throughout the RDD procedure was 0.76 mg (0.4-1.2mg), with a median infusion rate of 8 mL/h (4- 15ml/h), and median maximum AI rate of 3.33 μg/min (2-5.3 μg/min).
Conclusions
AI is a useful and safe therapeutic tool for selected high-risk desensitization procedures, mitigating severe DHR with mostly minor AEs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy Department, University Hospital Vall d'Hebron, Barcelona, Spain.
- Allergy Research Unit, Immune-mediated Diseases Research Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
- Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
Zitieren
APA
Gil-Serrano, J., Galvan-Blasco, P., Pereira-Gonzalez, J., Salvany-Pijuan, A., Gonzalez Di-Paolo, M., Guilarte, M., Luengo, O., Sala-Cunill, A., Cardona, V., & Labrador-Horrillo, M. (2025). Adrenaline: A Lifeline for Rapid Drug Desensitization in Hypersensitive Patients. Journal of Investigational Allergy and Clinical Immunology. https://doi.org/10.18176/jiaci.1075
Vancouver
Gil-Serrano J, Galvan-Blasco P, Pereira-Gonzalez J, Salvany-Pijuan A, Gonzalez Di-Paolo M, Guilarte M, et al. Adrenaline: A Lifeline for Rapid Drug Desensitization in Hypersensitive Patients. Journal of Investigational Allergy and Clinical Immunology. 2025. doi:10.18176/jiaci.1075
BibTeX
@article{GilSerrano2025,
author = {Gil-Serrano, Johana and Galvan-Blasco, Paula and Pereira-Gonzalez, Javier and Salvany-Pijuan, Arnau and Gonzalez Di-Paolo, Mercedes and Guilarte, Mar and Luengo, Olga and Sala-Cunill, Anna and Cardona, Victoria and Labrador-Horrillo, Moisés},
title = {Adrenaline: A Lifeline for Rapid Drug Desensitization in Hypersensitive Patients},
journal = {Journal of Investigational Allergy and Clinical Immunology},
year = {2025},
doi = {10.18176/jiaci.1075}
}
EUVIMED